.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,548,542

« Back to Dashboard

Details for Patent: 6,548,542

Title: Vision through photodynamic therapy of the eye
Abstract:Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.
Inventor(s): Strong; H. Andrew (North Van, CA), Levy; Julia (Vancouver, CA), Huber; Gustav (Zurich, CH), Fsadni; Mario (Buelach, CH)
Assignee: QLT Inc. (British Columbia, CA) Novartis, A.G. (CH)
Filing Date:Apr 28, 1999
Application Number:09/300,979
Claims:1. A method to improve visual acuity in a human subject afflicted with unwanted neovasculature in ocular tissue comprising irradiating the ocular tissue of said human subject with light emitted from a laser, wherein said subject has been identified as in need of improvement in visual acuity and suffering from unwanted neovasculature in ocular tissue, and administered a formulation of a purpurin sufficient to permit an effective amount to localize in said ocular tissue; wherein said irradiation is with light containing a wavelength absorbed by the purpurin and is conducted for a time and at an intensity sufficient to improve visual acuity in said subject.

2. A method to improve visual acuity in a human subject afflicted with unwanted neovasculature in ocular tissue comprising administering a formulation of a purpurin sufficient to permit an effective amount to localize in the ocular tissue of a human subject identified as in need of improvement in visual acuity and suffering from unwanted neovasculature in ocular tissue, and irradiating the ocular tissue with light emitted from a laser; wherein said irradiation is with light containing a wavelength absorbed by the purpurin and is conducted for a time and at an intensity sufficient to improve visual acuity in said subject.

3. A method to improve visual acuity in a human subject afflicted with unwanted neovasculature in ocular tissue comprising identifying,a human subject in need of improvement in visual acuity and suffering from unwanted neovasculature in ocular tissue, administering a formulation of a purpurin sufficient to permit an effective amount to localize in said ocular tissue, irradiating said ocular tissue in said subject with light emitted from a laser wherein said irradiation is with light containing a wavelength absorbed by the purpurin and is conducted for a time and at an intensity sufficient to improve visual acuity in said subject.

4. The method of any one of claims 1-3 wherein said neovasculature is choroidal vasculature.

5. The method of any one of claims 1-3 wherein said subject has been diagnosed with age-related macular degeneration (AMD).

6. The method of any one of claims 1-3 wherein said subject has been diagnosed with a condition selected from the group consisting of macular degeneration, ocular histoplasmosis syndrome, myopia, and inflammatory diseases.

7. The method of any one of claims 1-3 wherein said irradiation is administered beginning about 5-30 minutes after said subject has been administered said formulation.

8. The method of any one of claims 1-3 wherein said irradiation is administered beginning about 10-25 minutes after said subject has been administered said formulation.

9. The method of claim 4 wherein said irradiation is administered beginning about 10-25 minutes after said subject has been administered said formulation.

10. The method of claim 5 wherein said irradiation is administered beginning about 10-25 minutes after said subject has been administered said formulation.

11. The method of claim 6 wherein said irradiation is administered beginning about 10-25 minutes after said subject has been administered said formulation.

12. The method of any one of claims 1-3 wherein said irradiation is at 150-600 mW/cm.sup.2.

13. The method of claim 4 wherein said irradiation is at 150-600 mW/cm.sup.2.

14. The method of claim 5 wherein said irradiation is at 150-600 mW/cm.sup.2.

15. The method of claim 6 wherein said irradiation is at 150-600 mW/cm.sup.2.

16. The method of claim 7 wherein said irradiation is at 150-600 mW/cm.sup.2.

17. The method of claim 8 wherein said irradiation is at 150-600 mW/cm.sup.2.

18. The method of any one of claims 1-3 wherein said formulation is a liposomal formulation.

19. A method to improve visual acuity in a human subject afflicted with unwanted neovasculature in ocular tissue comprising irradiating the ocular tissue of said human subject with light emitted from a laser, wherein said subject has been identified as in need of improvement in visual acuity and suffering from unwanted neovasculature in ocular tissue, and administered a formulation of a photoactive compound sufficient to permit an effective amount to localize in said ocular tissue; wherein said irradiation is with light containing a wavelength absorbed by the photoactive compound and is conducted for a time and at an intensity sufficient to improve visual acuity in said subject.

20. The method of claim 19 wherein said photoactive compound is a purpurin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc